Patients in the cumulative clinical endpoint cohort were older; more likely to have atrial fibrillation and diabetes mellitus; be in CKD stages 1–3; and have dilated cardiomyopathy, higher LAVI and lower irisin levels than those in the free endpoint cohort. The gene discussed is FNDC5; the disease is diabetes mellitus.